Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 23, 2025 07:00 ET | Source: Castle Biosciences, Inc.

FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test

Castle announced that its DecisionDx®-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
July 22, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight

New York, USA, July 22, 2025 (GLOBE NEWSWIRE) -- Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight The...
July 09, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
May 29, 2025 16:30 ET | Source: Castle Biosciences, Inc.

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

Castle will present new data aimed at enhancing the clinical management of patients with cutaneous melanoma and uveal melanoma at ASCO 2025.
May 05, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
May 05, 2025 09:33 ET | Source: Research and Markets

Oncology Liquid Biopsy Market Outlook 2025-2035: Early Detection and Personalized Medicine Propel Widespread Adoption of Liquid Biopsy Technologies

Dublin, May 05, 2025 (GLOBE NEWSWIRE) -- The "Oncology Liquid Biopsy Market - A Global and Regional Analysis: Focus on Offering, Indication, Clinical Application, End User and Country-Level Analysis...
April 30, 2025 17:00 ET | Source: Castle Biosciences, Inc.

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Castle announced the publication of a new study demonstrating DecisionDx-Melanoma outperforms AJCC staging and the CP-GEP test.
April 25, 2025 16:15 ET | Source: Castle Biosciences, Inc.

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

Castle Biosciences will share new data intended to improve the care of patients with cutaneous and uveal melanoma at the AACR Annual Meeting 2025.
April 25, 2025 07:43 ET | Source: Junshi Biosciences

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma

Toripalimab was approved by the NMPA as the first-line treatment for unresectable or metastatic melanoma, the 12th indication in the Chinese mainland.
April 21, 2025 08:45 ET | Source: Vaccinex, Inc.

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Unique mechanism of pepinemab induced abundant, mature TLS, correlating with durable clinical benefit in HNSCC and in neoadjuvant study in melanoma.

Next Page keyboard_arrow_right